Related Experiment Video
Updated: Jun 21, 2026
07:43
Plasmid Stability Analysis with Open-Source Droplet Microfluidics
Published on: December 27, 2024
Structural instability of plasmid biopharmaceuticals: challenges and implications
Pedro H Oliveira1, Kristala Jones Prather, Duarte M F Prazeres
1Institute for Biotechnology and Bioengineering, Center for Biological and Chemical Engineering, Instituto Superior Técnico, Av. Rovisco Pais 1049-001 Lisbon, Portugal.
Trends in Biotechnology
|August 7, 2009
Summary
Ensuring the structural integrity of therapeutic plasmid DNA (pDNA) is crucial for developing safe and effective DNA-based therapies. This review highlights key instability factors in pDNA that must be addressed for improved molecular design.
Area of Science:
- Molecular Biology
- Biotechnology
- Pharmaceutical Sciences
Background:
- Therapeutic plasmid DNA (pDNA) applications are increasing globally.
- Development of pDNA-based therapeutics requires large quantities of stable, purified molecules.
- Ensuring the structural integrity of pDNA is a significant challenge during development.
Purpose of the Study:
- To review major determinants of structural instability in therapeutic plasmid DNA (pDNA).
- To identify key factors that compromise pDNA integrity.
- To inform the design of safer and more efficient pDNA molecules.
Main Methods:
- Literature review focusing on pDNA instability.
- Analysis of mutations triggered by sequence repeats.
- Examination of instability during intracellular routing.
- Investigation of insertion sequence-mediated instability and host genome integration.
Main Results:
- Repeated sequences are a major source of pDNA mutations.
- Instability events occur during pDNA's intracellular journey.
- Insertion sequences and host genome integration contribute to pDNA instability.
Conclusions:
- Eliminating major instability determinants is key to designing improved therapeutic pDNA.
- Addressing these instability factors will enhance the safety and efficacy of DNA therapeutics.
- Understanding pDNA instability is critical for advancing gene therapy and DNA-based medicines.
Related Concept Videos
01:28Plasmids
Plasmids are extrachromosomal DNA molecules found in bacteria, archaea, and some eukaryotic microbes like yeast. These small, circular DNA structures typically contain fewer than 30 genes, although some may exist linearly. Plasmids vary in their number within a cell, known as copy number. Single-copy plasmids are present in one copy per cell and multi-copy plasmids are present in multiple copies, reaching over 100 copies per cell.Plasmids usually replicate independently of the chromosomal DNA...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...